Global DNA Diagnostics Market Size Study, by Product Type (Instruments, Reagents, Service & Software), by Technology (PCR, Microarray, In-situ Hybridization, Sequencing Technology, Mass Spectrometry, Others), by Applications (Oncology, Infectious Disease,

Global DNA Diagnostics Market Size Study, by Product Type (Instruments, Reagents, Service & Software), by Technology (PCR, Microarray, In-situ Hybridization, Sequencing Technology, Mass Spectrometry, Others), by Applications (Oncology, Infectious Disease, Myogenic Disorder, Clinical Diagnostic Confirmation, Prenatal Diagnostics, Pre-implantation Diagnostics, Others), by End-Users (Point of Care, Diagnostic Center, Self Testing/OTC), and Regional Forecasts 2022-2032

Global DNA diagnostics market is valued at approximately USD 25.15 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 9.8% over the forecast period 2024-2032. DNA diagnostics, a groundbreaking methodology in medical diagnostics, empowers healthcare professionals to detect various diseases, including cancer, infectious diseases, and myogenic disorders, and to tailor appropriate treatments. This technique is integral to clinical diagnostic confirmation and prenatal diagnostics, stemming from advancements in the Human Genome Project, which unveiled numerous disease-causing agents. Technological progress has significantly enhanced DNA diagnostic platforms and techniques. Prominent technologies in DNA diagnostics encompass polymerase chain reaction (PCR), microarray techniques, sequencing technology, and mass spectrometry. These technologies facilitate crucial processes like sample preparation and DNA isolation. The continuous improvement in these methodologies drives the market's growth. Furthermore, the application of DNA diagnostics in prenatal diagnostics and clinical confirmations has further accelerated market expansion.

The DNA diagnostics market is poised for substantial growth in the foreseeable future, propelled by innovations in product design and technology. This shift has encouraged medical professionals and researchers to transition from traditional diagnostic methods to personalized medicines, which will positively influence market growth. Next-generation sequencing (NGS) stands out as a potent tool for decoding numerous human diseases, including various cancers. NGS reduces sequencing costs and enhances throughput, significantly impacting the DNA diagnostics market.

The market is segmented based on product type, technology, application, end-users, and geography. Instruments, reagents, and service & software constitute the product type segmentation, with instruments holding the dominant share due to enhanced healthcare facilities, user-friendly features, competitive cost structure, and growing demand. The service & software segment is projected to grow steadily, driven by technological advancements and IT integration in DNA diagnostics.

PCR dominates the technology segment owing to its extensive use in diagnostic procedures like sample preparation and DNA separation. The market is also segmented by application into oncology, infectious diseases, and myogenic disorders, with oncology leading due to the rising incidence of cancer and an aging population.

The key regions considered for the global DNA Diagnostics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the DNA Diagnostics Market in terms of revenue. The market growth in the region is being attributed to factors including high DNA diagnostics adoption rates and the prevalence of chronic and infectious diseases. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by a large and growing population that creates high demand for healthcare services. Governments in the region are also increasingly funding research and development of DNA testing technologies. This, combined with a rising burden of chronic diseases like cancer, creates lucrative prospects for market growth over the anticipated years.

Major market players included in this report are:

Illumina, Inc.

Bayer Diagnostic

Cephide Inc.

Thermo Fisher Scientific

Gen-probe Inc. (Hologic)

Johnson and Johnson

Bio-Rad Laboratories

Roche Diagnostics

Novartis

Abbott Laboratories

The detailed segments and sub-segment of the market are explained below:

By Product Type
• Instruments
• Reagents
• Service & Software

By Technology
• PCR
• Microarray
• In-situ Hybridization
• Sequencing Technology
• Mass Spectrometry
• Others

By Applications
• Oncology
• Infectious Disease
• Myogenic Disorder
• Clinical Diagnostic Confirmation
• Prenatal Diagnostics
• Pre-implantation Diagnostics
• Others

By End-Users
• Point of Care
• Diagnostic Center
• Self-Testing/OTC

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico
• RoLA

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.